APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Radioligands Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Therapeutic Radioligands Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025190 pages

Choose your research edition.

Industry ResearchTherapeutic Radioligands Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Radioligands Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Therapeutic Radioligands Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Radioligands Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Radioligands Drug Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Therapeutic Radioligands Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Therapeutic Radioligands Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Therapeutic Radioligands Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Therapeutic Radioligands Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Therapeutic Radioligands Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Therapeutic Radioligands Drug include Novartis, Mundipharma, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med and Nordic Nanovector, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Therapeutic Radioligands Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Therapeutic Radioligands Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Therapeutic Radioligands Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Therapeutic Radioligands Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Therapeutic Radioligands Drug Segment by Company

Novartis

Mundipharma

Bayer

Y-mAbs Therapeutics

Telix Pharmaceuticals

RadioMedix

Philogen

Orano Med

Nordic Nanovector

Lantheus

Gilead Sciences

Fusion Pharmaceuticals

Curium Pharmaceuticals

Curasight

Clarity Pharmaceuticals

China Isotope & Radiation

Aurobindo Pharma

Actinium Pharmaceuticals

Therapeutic Radioligands Drug Segment by Type

Beta-emitting

Targeted Alpha Therapy

Therapeutic Radioligands Drug Segment by Application

Solid Tumor

Non Hodgkin Lymphoma

Therapeutic Radioligands Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Radioligands Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Radioligands Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Radioligands Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Therapeutic Radioligands Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Radioligands Drug industry.

Chapter 3: Detailed analysis of Therapeutic Radioligands Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Therapeutic Radioligands Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Therapeutic Radioligands Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Beta-emitting Table 3. Key Players of Targeted Alpha Therapy Table 4. Global Therapeutic Radioligands Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Solid Tumor Table 6. Key Players of Non Hodgkin Lymphoma Table 7. Global Therapeutic Radioligands Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global Therapeutic Radioligands Drug Market Size by Region (2021-2026) & (US$ Million) Table 9. Global Therapeutic Radioligands Drug Market Share by Region (2021-2026) Table 10. Global Therapeutic Radioligands Drug Market Size by Region (2027-2032) & (US$ Million) Table 11. Global Therapeutic Radioligands Drug Market Share by Region (2027-2032) Table 12. Therapeutic Radioligands Drug Industry Trends Table 13. Therapeutic Radioligands Drug Industry Drivers Table 14. Therapeutic Radioligands Drug Industry Opportunities and Challenges Table 15. Therapeutic Radioligands Drug Industry Restraints Table 16. Global Therapeutic Radioligands Drug Revenue by Company (US$ Million) & (2021-2026) Table 17. Global Therapeutic Radioligands Drug Revenue Market Share by Company (2021-2026) Table 18. Global Therapeutic Radioligands Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global Therapeutic Radioligands Drug Key Company Head Office and Area Served Table 20. Global Therapeutic Radioligands Drug Company, Product Type & Application Table 21. Global Therapeutic Radioligands Drug Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global Therapeutic Radioligands Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global Therapeutic Radioligands Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Therapeutic Radioligands Drug Market Size by Type (2021-2026) & (US$ Million) Table 26. Global Therapeutic Radioligands Drug Market Size by Type (2027-2032) & (US$ Million) Table 27. Global Therapeutic Radioligands Drug Revenue Market Share by Type (2021-2026) Table 28. Global Therapeutic Radioligands Drug Revenue Market Share by Type (2027-2032) Table 29. Global Therapeutic Radioligands Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Therapeutic Radioligands Drug Market Size by Application (2021-2026) & (US$ Million) Table 31. Global Therapeutic Radioligands Drug Market Size by Application (2027-2032) & (US$ Million) Table 32. Global Therapeutic Radioligands Drug Revenue Market Share by Application (2021-2026) Table 33. Global Therapeutic Radioligands Drug Revenue Market Share by Application (2027-2032) Table 34. Novartis Company Information Table 35. Novartis Business Overview Table 36. Novartis Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Novartis Therapeutic Radioligands Drug Product Portfolio Table 38. Novartis Recent Development Table 39. Mundipharma Company Information Table 40. Mundipharma Business Overview Table 41. Mundipharma Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Mundipharma Therapeutic Radioligands Drug Product Portfolio Table 43. Mundipharma Recent Development Table 44. Bayer Company Information Table 45. Bayer Business Overview Table 46. Bayer Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Bayer Therapeutic Radioligands Drug Product Portfolio Table 48. Bayer Recent Development Table 49. Y-mAbs Therapeutics Company Information Table 50. Y-mAbs Therapeutics Business Overview Table 51. Y-mAbs Therapeutics Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Portfolio Table 53. Y-mAbs Therapeutics Recent Development Table 54. Telix Pharmaceuticals Company Information Table 55. Telix Pharmaceuticals Business Overview Table 56. Telix Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Telix Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio Table 58. Telix Pharmaceuticals Recent Development Table 59. RadioMedix Company Information Table 60. RadioMedix Business Overview Table 61. RadioMedix Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. RadioMedix Therapeutic Radioligands Drug Product Portfolio Table 63. RadioMedix Recent Development Table 64. Philogen Company Information Table 65. Philogen Business Overview Table 66. Philogen Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Philogen Therapeutic Radioligands Drug Product Portfolio Table 68. Philogen Recent Development Table 69. Orano Med Company Information Table 70. Orano Med Business Overview Table 71. Orano Med Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Orano Med Therapeutic Radioligands Drug Product Portfolio Table 73. Orano Med Recent Development Table 74. Nordic Nanovector Company Information Table 75. Nordic Nanovector Business Overview Table 76. Nordic Nanovector Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Nordic Nanovector Therapeutic Radioligands Drug Product Portfolio Table 78. Nordic Nanovector Recent Development Table 79. Lantheus Company Information Table 80. Lantheus Business Overview Table 81. Lantheus Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Lantheus Therapeutic Radioligands Drug Product Portfolio Table 83. Lantheus Recent Development Table 84. Gilead Sciences Company Information Table 85. Gilead Sciences Business Overview Table 86. Gilead Sciences Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Gilead Sciences Therapeutic Radioligands Drug Product Portfolio Table 88. Gilead Sciences Recent Development Table 89. Fusion Pharmaceuticals Company Information Table 90. Fusion Pharmaceuticals Business Overview Table 91. Fusion Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 92. Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio Table 93. Fusion Pharmaceuticals Recent Development Table 94. Curium Pharmaceuticals Company Information Table 95. Curium Pharmaceuticals Business Overview Table 96. Curium Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 97. Curium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio Table 98. Curium Pharmaceuticals Recent Development Table 99. Curasight Company Information Table 100. Curasight Business Overview Table 101. Curasight Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 102. Curasight Therapeutic Radioligands Drug Product Portfolio Table 103. Curasight Recent Development Table 104. Clarity Pharmaceuticals Company Information Table 105. Clarity Pharmaceuticals Business Overview Table 106. Clarity Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 107. Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio Table 108. Clarity Pharmaceuticals Recent Development Table 109. China Isotope & Radiation Company Information Table 110. China Isotope & Radiation Business Overview Table 111. China Isotope & Radiation Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 112. China Isotope & Radiation Therapeutic Radioligands Drug Product Portfolio Table 113. China Isotope & Radiation Recent Development Table 114. Aurobindo Pharma Company Information Table 115. Aurobindo Pharma Business Overview Table 116. Aurobindo Pharma Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 117. Aurobindo Pharma Therapeutic Radioligands Drug Product Portfolio Table 118. Aurobindo Pharma Recent Development Table 119. Actinium Pharmaceuticals Company Information Table 120. Actinium Pharmaceuticals Business Overview Table 121. Actinium Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 122. Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio Table 123. Actinium Pharmaceuticals Recent Development Table 124. North America Therapeutic Radioligands Drug Market Size by Type (2021-2026) & (US$ Million) Table 125. North America Therapeutic Radioligands Drug Market Size by Type (2027-2032) & (US$ Million) Table 126. North America Therapeutic Radioligands Drug Market Size by Application (2021-2026) & (US$ Million) Table 127. North America Therapeutic Radioligands Drug Market Size by Application (2027-2032) & (US$ Million) Table 128. North America Therapeutic Radioligands Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. North America Therapeutic Radioligands Drug Market Size by Country (2021-2026) Table 130. North America Therapeutic Radioligands Drug Market Size by Country (2027-2032) Table 131. Europe Therapeutic Radioligands Drug Market Size by Type (2021-2026) & (US$ Million) Table 132. Europe Therapeutic Radioligands Drug Market Size by Type (2027-2032) & (US$ Million) Table 133. Europe Therapeutic Radioligands Drug Market Size by Application (2021-2026) & (US$ Million) Table 134. Europe Therapeutic Radioligands Drug Market Size by Application (2027-2032) & (US$ Million) Table 135. Europe Therapeutic Radioligands Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. Europe Therapeutic Radioligands Drug Market Size by Country (2021-2026) Table 137. Europe Therapeutic Radioligands Drug Market Size by Country (2027-2032) Table 138. China Therapeutic Radioligands Drug Market Size by Type (2021-2026) & (US$ Million) Table 139. China Therapeutic Radioligands Drug Market Size by Type (2027-2032) & (US$ Million) Table 140. China Therapeutic Radioligands Drug Market Size by Application (2021-2026) & (US$ Million) Table 141. China Therapeutic Radioligands Drug Market Size by Application (2027-2032) & (US$ Million) Table 142. Asia Therapeutic Radioligands Drug Market Size by Type (2021-2026) & (US$ Million) Table 143. Asia Therapeutic Radioligands Drug Market Size by Type (2027-2032) & (US$ Million) Table 144. Asia Therapeutic Radioligands Drug Market Size by Application (2021-2026) & (US$ Million) Table 145. Asia Therapeutic Radioligands Drug Market Size by Application (2027-2032) & (US$ Million) Table 146. Asia Therapeutic Radioligands Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Asia Therapeutic Radioligands Drug Market Size by Country (2021-2026) Table 148. Asia Therapeutic Radioligands Drug Market Size by Country (2027-2032) Table 149. South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Type (2021-2026) & (US$ Million) Table 150. South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Type (2027-2032) & (US$ Million) Table 151. South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Application (2021-2026) & (US$ Million) Table 152. South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Application (2027-2032) & (US$ Million) Table 153. South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2021-2026) Table 155. South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2027-2032) Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Therapeutic Radioligands Drug Product Image Figure 2. Global Therapeutic Radioligands Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Therapeutic Radioligands Drug Market Share by Type: 2025 VS 2032 Figure 4. Beta-emitting Image Figure 5. Targeted Alpha Therapy Image Figure 6. Global Therapeutic Radioligands Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Therapeutic Radioligands Drug Market Share by Application: 2025 VS 2032 Figure 8. Solid Tumor Image Figure 9. Non Hodgkin Lymphoma Image Figure 10. Global Therapeutic Radioligands Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 12. Global Therapeutic Radioligands Drug Market Share by Region: 2025 VS 2032 Figure 13. Years Considered Figure 14. Global Therapeutic Radioligands Drug Market Share by Players in 2025 Figure 15. Global Top 5 and 10 Therapeutic Radioligands Drug Players Market Share by Revenue in 2025 Figure 16. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Therapeutic Radioligands Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Therapeutic Radioligands Drug Revenue Market Share by Type (2021-2032) Figure 19. Global Therapeutic Radioligands Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Therapeutic Radioligands Drug Revenue Market Share by Application (2021-2032) Figure 21. North America Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 22. North America Therapeutic Radioligands Drug Market Share by Type (2021-2032) Figure 23. North America Therapeutic Radioligands Drug Market Share by Application (2021-2032) Figure 24. North America Therapeutic Radioligands Drug Market Share by Country (2021-2032) Figure 25. United States Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 26. Canada Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 27. Mexico Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 28. Europe Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 29. Europe Therapeutic Radioligands Drug Market Share by Type (2021-2032) Figure 30. Europe Therapeutic Radioligands Drug Market Share by Application (2021-2032) Figure 31. Europe Therapeutic Radioligands Drug Market Share by Country (2021-2032) Figure 32. Germany Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 33. France Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 34. U.K. Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 35. Italy Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 36. Russia Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 37. Nordic Countries Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 38. China Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 39. China Therapeutic Radioligands Drug Market Share by Type (2021-2032) Figure 40. China Therapeutic Radioligands Drug Market Share by Application (2021-2032) Figure 41. Asia Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 42. Asia Therapeutic Radioligands Drug Market Share by Type (2021-2032) Figure 43. Asia Therapeutic Radioligands Drug Market Share by Application (2021-2032) Figure 44. Asia Therapeutic Radioligands Drug Market Share by Country (2021-2032) Figure 45. Japan Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 46. South Korea Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 47. Taiwan Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 48. Southeast Asia Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 49. India Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 50. Australia Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 51. South America, Middle East & Africa Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Therapeutic Radioligands Drug Market Share by Type (2021-2032) Figure 53. South America, Middle East & Africa Therapeutic Radioligands Drug Market Share by Application (2021-2032) Figure 54. South America, Middle East & Africa Therapeutic Radioligands Drug Market Share by Country (2021-2032) Figure 55. Brazil Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 56. South Africa Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 58. Turkey Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 59. Argentina Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 60. UAE Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 61. Egypt Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 62. Chile Therapeutic Radioligands Drug Market Size (2021-2032) & (US$ Million) Figure 63. Research Process Figure 64. Key Executives Interviewed

Scope & coverage.

Types
  • Beta-emitting
  • Targeted Alpha Therapy
Applications
  • Solid Tumor
  • Non Hodgkin Lymphoma
Companies covered
  • Novartis
  • Mundipharma
  • Bayer
  • Y-mAbs Therapeutics
  • Telix Pharmaceuticals
  • RadioMedix
  • Philogen
  • Orano Med
  • Nordic Nanovector
  • Lantheus
  • Gilead Sciences
  • Fusion Pharmaceuticals
  • Curium Pharmaceuticals
  • Curasight
  • Clarity Pharmaceuticals
  • China Isotope & Radiation
  • Aurobindo Pharma
  • Actinium Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Therapeutic Radioligands Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Beta-emitting
  5. 1.2.3 Targeted Alpha Therapy
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Therapeutic Radioligands Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Solid Tumor
  9. 1.3.3 Non Hodgkin Lymphoma
  10. 1.4 Global Market Growth Prospects
  11. 1.5 Global Therapeutic Radioligands Drug Growth Trends by Region
  12. 1.5.1 Global Therapeutic Radioligands Drug Market Size by Region: 2021 VS 2025 VS 2032
  13. 1.5.2 Therapeutic Radioligands Drug Market Size by Region (2021-2026)
  14. 1.5.3 Therapeutic Radioligands Drug Market Size by Region (2027-2032)
  15. 1.6 Assumptions and Limitations
  16. 1.7 Study Goals and Objectives
  17. 1.8 Years Considered
2 Global Therapeutic Radioligands Drug Market Dynamics
  1. 2.1 Therapeutic Radioligands Drug Industry Trends
  2. 2.2 Therapeutic Radioligands Drug Industry Drivers
  3. 2.3 Therapeutic Radioligands Drug Industry Opportunities and Challenges
  4. 2.4 Therapeutic Radioligands Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Therapeutic Radioligands Drug Revenue by Company (2021-2026)
  2. 3.2 Global Therapeutic Radioligands Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Therapeutic Radioligands Drug Key Company Head office and Area Served
  4. 3.4 Global Therapeutic Radioligands Drug Company, Product Type & Application
  5. 3.5 Global Therapeutic Radioligands Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Therapeutic Radioligands Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Therapeutic Radioligands Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Therapeutic Radioligands Drug Tier 1, Tier 2, and Tier 3
4 Therapeutic Radioligands Drug Market by Type
  1. 4.1 Global Therapeutic Radioligands Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Therapeutic Radioligands Drug Market Size by Type (2021-2032)
  3. 4.3 Global Therapeutic Radioligands Drug Market Size Share by Type (2021-2032)
5 Therapeutic Radioligands Drug Market by Application
  1. 5.1 Global Therapeutic Radioligands Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Therapeutic Radioligands Drug Market Size by Application (2021-2032)
  3. 5.3 Global Therapeutic Radioligands Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Novartis
  2. 6.1.1 Novartis Company Information
  3. 6.1.2 Novartis Business Overview
  4. 6.1.3 Novartis Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Novartis Therapeutic Radioligands Drug Product Portfolio
  6. 6.1.5 Novartis Recent Developments
  7. 6.2 Mundipharma
  8. 6.2.1 Mundipharma Company Information
  9. 6.2.2 Mundipharma Business Overview
  10. 6.2.3 Mundipharma Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Mundipharma Therapeutic Radioligands Drug Product Portfolio
  12. 6.2.5 Mundipharma Recent Developments
  13. 6.3 Bayer
  14. 6.3.1 Bayer Company Information
  15. 6.3.2 Bayer Business Overview
  16. 6.3.3 Bayer Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Bayer Therapeutic Radioligands Drug Product Portfolio
  18. 6.3.5 Bayer Recent Developments
  19. 6.4 Y-mAbs Therapeutics
  20. 6.4.1 Y-mAbs Therapeutics Company Information
  21. 6.4.2 Y-mAbs Therapeutics Business Overview
  22. 6.4.3 Y-mAbs Therapeutics Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Portfolio
  24. 6.4.5 Y-mAbs Therapeutics Recent Developments
  25. 6.5 Telix Pharmaceuticals
  26. 6.5.1 Telix Pharmaceuticals Company Information
  27. 6.5.2 Telix Pharmaceuticals Business Overview
  28. 6.5.3 Telix Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Telix Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
  30. 6.5.5 Telix Pharmaceuticals Recent Developments
  31. 6.6 RadioMedix
  32. 6.6.1 RadioMedix Company Information
  33. 6.6.2 RadioMedix Business Overview
  34. 6.6.3 RadioMedix Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 RadioMedix Therapeutic Radioligands Drug Product Portfolio
  36. 6.6.5 RadioMedix Recent Developments
  37. 6.7 Philogen
  38. 6.7.1 Philogen Company Information
  39. 6.7.2 Philogen Business Overview
  40. 6.7.3 Philogen Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Philogen Therapeutic Radioligands Drug Product Portfolio
  42. 6.7.5 Philogen Recent Developments
  43. 6.8 Orano Med
  44. 6.8.1 Orano Med Company Information
  45. 6.8.2 Orano Med Business Overview
  46. 6.8.3 Orano Med Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Orano Med Therapeutic Radioligands Drug Product Portfolio
  48. 6.8.5 Orano Med Recent Developments
  49. 6.9 Nordic Nanovector
  50. 6.9.1 Nordic Nanovector Company Information
  51. 6.9.2 Nordic Nanovector Business Overview
  52. 6.9.3 Nordic Nanovector Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Nordic Nanovector Therapeutic Radioligands Drug Product Portfolio
  54. 6.9.5 Nordic Nanovector Recent Developments
  55. 6.10 Lantheus
  56. 6.10.1 Lantheus Company Information
  57. 6.10.2 Lantheus Business Overview
  58. 6.10.3 Lantheus Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Lantheus Therapeutic Radioligands Drug Product Portfolio
  60. 6.10.5 Lantheus Recent Developments
  61. 6.11 Gilead Sciences
  62. 6.11.1 Gilead Sciences Company Information
  63. 6.11.2 Gilead Sciences Business Overview
  64. 6.11.3 Gilead Sciences Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Gilead Sciences Therapeutic Radioligands Drug Product Portfolio
  66. 6.11.5 Gilead Sciences Recent Developments
  67. 6.12 Fusion Pharmaceuticals
  68. 6.12.1 Fusion Pharmaceuticals Company Information
  69. 6.12.2 Fusion Pharmaceuticals Business Overview
  70. 6.12.3 Fusion Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
  72. 6.12.5 Fusion Pharmaceuticals Recent Developments
  73. 6.13 Curium Pharmaceuticals
  74. 6.13.1 Curium Pharmaceuticals Company Information
  75. 6.13.2 Curium Pharmaceuticals Business Overview
  76. 6.13.3 Curium Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Curium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
  78. 6.13.5 Curium Pharmaceuticals Recent Developments
  79. 6.14 Curasight
  80. 6.14.1 Curasight Company Information
  81. 6.14.2 Curasight Business Overview
  82. 6.14.3 Curasight Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Curasight Therapeutic Radioligands Drug Product Portfolio
  84. 6.14.5 Curasight Recent Developments
  85. 6.15 Clarity Pharmaceuticals
  86. 6.15.1 Clarity Pharmaceuticals Company Information
  87. 6.15.2 Clarity Pharmaceuticals Business Overview
  88. 6.15.3 Clarity Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
  90. 6.15.5 Clarity Pharmaceuticals Recent Developments
  91. 6.16 China Isotope & Radiation
  92. 6.16.1 China Isotope & Radiation Company Information
  93. 6.16.2 China Isotope & Radiation Business Overview
  94. 6.16.3 China Isotope & Radiation Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 China Isotope & Radiation Therapeutic Radioligands Drug Product Portfolio
  96. 6.16.5 China Isotope & Radiation Recent Developments
  97. 6.17 Aurobindo Pharma
  98. 6.17.1 Aurobindo Pharma Company Information
  99. 6.17.2 Aurobindo Pharma Business Overview
  100. 6.17.3 Aurobindo Pharma Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Aurobindo Pharma Therapeutic Radioligands Drug Product Portfolio
  102. 6.17.5 Aurobindo Pharma Recent Developments
  103. 6.18 Actinium Pharmaceuticals
  104. 6.18.1 Actinium Pharmaceuticals Company Information
  105. 6.18.2 Actinium Pharmaceuticals Business Overview
  106. 6.18.3 Actinium Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
  108. 6.18.5 Actinium Pharmaceuticals Recent Developments
7 North America
  1. 7.1 North America Therapeutic Radioligands Drug Market Size (2021-2032)
  2. 7.2 North America Therapeutic Radioligands Drug Market Size by Type
  3. 7.2.1 North America Therapeutic Radioligands Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America Therapeutic Radioligands Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America Therapeutic Radioligands Drug Market Share by Type (2021-2032)
  6. 7.3 North America Therapeutic Radioligands Drug Market Size by Application
  7. 7.3.1 North America Therapeutic Radioligands Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America Therapeutic Radioligands Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America Therapeutic Radioligands Drug Market Share by Application (2021-2032)
  10. 7.4 North America Therapeutic Radioligands Drug Market Size by Country
  11. 7.4.1 North America Therapeutic Radioligands Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Therapeutic Radioligands Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America Therapeutic Radioligands Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America Therapeutic Radioligands Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Therapeutic Radioligands Drug Market Size (2021-2032)
  2. 8.2 Europe Therapeutic Radioligands Drug Market Size by Type
  3. 8.2.1 Europe Therapeutic Radioligands Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe Therapeutic Radioligands Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe Therapeutic Radioligands Drug Market Share by Type (2021-2032)
  6. 8.3 Europe Therapeutic Radioligands Drug Market Size by Application
  7. 8.3.1 Europe Therapeutic Radioligands Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe Therapeutic Radioligands Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe Therapeutic Radioligands Drug Market Share by Application (2021-2032)
  10. 8.4 Europe Therapeutic Radioligands Drug Market Size by Country
  11. 8.4.1 Europe Therapeutic Radioligands Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Therapeutic Radioligands Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe Therapeutic Radioligands Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe Therapeutic Radioligands Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Therapeutic Radioligands Drug Market Size (2021-2032)
  2. 9.2 China Therapeutic Radioligands Drug Market Size by Type
  3. 9.2.1 China Therapeutic Radioligands Drug Market Size by Type (2021-2026)
  4. 9.2.2 China Therapeutic Radioligands Drug Market Size by Type (2027-2032)
  5. 9.2.3 China Therapeutic Radioligands Drug Market Share by Type (2021-2032)
  6. 9.3 China Therapeutic Radioligands Drug Market Size by Application
  7. 9.3.1 China Therapeutic Radioligands Drug Market Size by Application (2021-2026)
  8. 9.3.2 China Therapeutic Radioligands Drug Market Size by Application (2027-2032)
  9. 9.3.3 China Therapeutic Radioligands Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Therapeutic Radioligands Drug Market Size (2021-2032)
  2. 10.2 Asia Therapeutic Radioligands Drug Market Size by Type
  3. 10.2.1 Asia Therapeutic Radioligands Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia Therapeutic Radioligands Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia Therapeutic Radioligands Drug Market Share by Type (2021-2032)
  6. 10.3 Asia Therapeutic Radioligands Drug Market Size by Application
  7. 10.3.1 Asia Therapeutic Radioligands Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia Therapeutic Radioligands Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia Therapeutic Radioligands Drug Market Share by Application (2021-2032)
  10. 10.4 Asia Therapeutic Radioligands Drug Market Size by Country
  11. 10.4.1 Asia Therapeutic Radioligands Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Therapeutic Radioligands Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia Therapeutic Radioligands Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia Therapeutic Radioligands Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Therapeutic Radioligands Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Therapeutic Radioligands Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Therapeutic Radioligands Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst